4Accepted Aug 3, 4:01 PM ET
Apnimed (APMD) Director Gary Receives and Surrenders Derivative Awards
Accepted (ET)
4:01 PM
Aug 3, 2026
Filed
Aug 3, 2026
Documents
1
Size
18.8 KB
Summary
Apnimed (APMD) Director Gary Receives and Surrenders Derivative Awards
What Happened
- Director Gary reported a series of derivative transactions with Apnimed (APMD) between July 30 and August 3, 2026. The filing shows 185,321 shares acquired (code A = grant/award) and 140,844 shares disposed to the issuer (code D), all at $0.00 per share (derivative transactions), resulting in net +44,477 derivative shares reported.
- These entries reflect awards/grants and reclassifications of derivative securities rather than open-market purchases or sales for cash.
Key Details
- Transaction dates: July 30, 2026 and August 3, 2026. All reported on Form 4 filed August 3, 2026.
- Prices/values: All transactions reported at $0.00 per share; total cash consideration shown as $0 (derivative transactions).
- Quantities: Acquired = 185,321 shares (aggregate); Disposed to issuer = 140,844 shares (aggregate); net change = +44,477 shares.
- Shares owned after transaction: Not specified in the provided excerpt of the filing.
- Footnotes of note:
- F1: A reclassification occurred (each Class A share reclassified into one share of Common Stock) under Rules 16b-7 and 16b-3.
- F2–F4: Vesting schedules apply to the options/awards (initial 25% cliff after 12 months for some grants, remainder vesting quarterly or monthly over 36 months thereafter).
- Filing timeliness: Form 4 was filed August 3, 2026; transactions occurred July 30 and August 3, 2026. The filing date is within the normal 2-business-day window for Form 4 reporting.
Context
- These were derivative grant/reclassification entries (not open-market buys or sales). Grants and reclassifications often reflect compensation, option activity, or administrative conversions and do not by themselves signal buying or selling for cash.
- For retail investors: pay attention to vesting terms (F2–F4) — future shares may vest over time, potentially leading to future open-market sales if exercised and sold, but the current filing documents only non-cash derivative awards and issuer-side dispositions.